{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:59:18Z","timestamp":1782197958919,"version":"3.54.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.09.009","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T15:47:27Z","timestamp":1505836047000},"page":"5756-5758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Risk of Guillain-Barr\u00e9 Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink"],"prefix":"10.1016","volume":"35","author":[{"given":"Julianne","family":"Gee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.09.009_b0005","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.009_b0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000339248","article-title":"Vaccine Safety Datalink Research T. Guillain-Barre syndrome incidence in a large United States cohort (2000\u20132009)","volume":"39","author":"Shui","year":"2012","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.vaccine.2017.09.009_b0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2105\/AJPH.2013.301651","article-title":"Cumulative risk of Guillain-Barre syndrome among vaccinated and unvaccinated populations during the 2009 H1N1 influenza pandemic","volume":"104","author":"Vellozzi","year":"2014","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2017.09.009_b0020","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain-Barre syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.009_b0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11882-011-0190-y","article-title":"Guillain-barre syndrome: modern theories of etiology","volume":"11","author":"Hardy","year":"2011","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.vaccine.2017.09.009_b0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2017.09.009_b0035","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.vaccine.2010.11.056","article-title":"Tdap and GBS letter","volume":"29","author":"Nordin","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.009_b0040","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pds.3353","article-title":"No risk of Guillain-Barre syndrome found after meningococcal conjugate vaccination in two large cohort studies","volume":"21","author":"Yih","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2017.09.009_b0045","doi-asserted-by":"crossref","first-page":"e67185","DOI":"10.1371\/journal.pone.0067185","article-title":"Guillain-Barre syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the vaccine safety Datalink, 2009\u20132011","volume":"8","author":"Greene","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.09.009_b0050","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.09.009_b0055","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006\u20132014--United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"10.1016\/j.vaccine.2017.09.009_b0060","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.vaccine.2010.11.031","article-title":"Comment on the contribution by Souayah et al., \u201cGuillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006\u20132009\u201d","volume":"29","author":"Slade","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.009_b0065","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"Bmj"},{"key":"10.1016\/j.vaccine.2017.09.009_b0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2017.09.009_b0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2017.09.009_b0080","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.009_b0085","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.vaccine.2017.06.030","article-title":"Human papillomavirus vaccination and risk of autoimmune diseases: a large cohort study of over 2 million young girls in France","volume":"35","author":"Miranda","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.009_b0090","unstructured":"Institute of Medicine CoAoSoHORttRCIS, Board on Population Health and Public Health Practice. Childhood immunization schedule and safety: stakeholder concerns, scientific evidence, and future studies; January 16, 2013"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2017.09.009_b0095","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2017.09.009_b0100","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T08:48:56Z","timestamp":1531558136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17312252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":20,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17312252"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Guillain-Barr\u00e9 Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}